Loading
A phase 2 trial of Paclitaxel / nab-paclitaxel in non-small-cell lung cancer and small-cell lung cancer, run by ToLymph Inc., now recruiting.
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer is a phase 2 interventional study registered as NCT06693336 by ToLymph Inc., with 42 participants planned, started 2024-11-18 and due to reach its primary completion in 2026-11-18. Interventions recorded: SMS001. Conditions listed: Carcinoma, Non-Small-Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Cytotoxic chemotherapy, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Paclitaxel / nab-paclitaxel, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Paclitaxel / nab-paclitaxel, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Paclitaxel / nab-paclitaxel, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Resectable stage I to III non-small-cell lung cancer, Paclitaxel / nab-paclitaxel, Small-cell lung cancer, Non-small-cell lung cancer.